POst-Market ClINical Follow-up STudy of the SerranatOR PTA Serration Balloon CathEter

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects intended to be treated with Serranator® for de-novo or restenotic lesions of the iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries or dysfunctional native or synthetic arteriovenous dialysis fistulae.

• Subjects presenting with claudication or critical limb-threatening ischemia (CLTI) by Rutherford Clinical Category 3, 4, 5, or 6 of the target limb.

• Age of subject is \> 18.

• Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.

Locations
United States
Texas
UT Southwestern
RECRUITING
Dallas
Contact Information
Primary
Alexis Shewfelt
ashewfelt33@cagentvascular.com
6502086743
Time Frame
Start Date: 2025-01-22
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 500
Treatments
Subjects
The study population will consist of subjects with claudication or ischemic rest pain, with de novo or restenotic lesions in the iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistulae.
Sponsors
Leads: Cagent Vascular LLC
Collaborators: Peachtree BioResearch Solutions Inc., Yale Cardiovascular Research Group

This content was sourced from clinicaltrials.gov